Silent Model Degradation Detection for API Customers
C7/10June 12, 2026
WhatA monitoring service that continuously probes LLM API endpoints with calibrated test prompts to detect undisclosed quality changes, capability regressions, or silent model swaps.
SignalSeveral commenters express deep anxiety that model providers silently degrade quality based on undisclosed criteria — the Dieselgate analogy was explicitly raised, and trust in consistent API behavior is eroding as providers optimize costs.
Why NowLLM providers now operate multiple model versions simultaneously and route traffic dynamically; the practice of silent downgrades has become widespread enough that developers are building workarounds and losing trust.
MarketCompanies spending $10K+/month on LLM APIs who need SLA-like quality guarantees; TAM is the $30B+ LLM API market's quality assurance layer. No established player monitors provider-side model integrity.
MoatHistorical baseline data across providers and model versions creates an irreplaceable comparison dataset — first mover accumulates months of longitudinal quality data that newcomers cannot retroactively obtain.
CRISPR Delivery Platform for Solid Tumor TherapeuticsP7/10A biotech company focused specifically on solving the delivery problem for CRISPR-based cancer therapies, developing novel lipid nanoparticle or viral vector systems that can efficiently transport CRISPR payloads to solid tumors in vivo.
CRISPR Cancer Diagnostics for Undruggable MutationsP6/10A diagnostic platform that profiles patients' tumors for the specific genomic amplifications and mutations that CRISPR-shredding approaches can target, enabling oncologists to match patients to emerging CRISPR therapies.
Biotech Translation Tracker for Informed InvestorsC5/10A platform that tracks the real progress of preclinical and clinical-stage biotech breakthroughs — from lab results through delivery challenges, trial phases, and regulatory milestones — giving investors and patients an honest, hype-free assessment of how close therapies actually are to market.
Viral Vector Therapy Development Platform as ServiceC6/10A contract development platform that helps biotech startups and academic labs design, optimize, and manufacture viral vector (AAV/lentivirus) delivery systems for gene therapies, positioning as the picks-and-shovels play in gene therapy.
Automated Cost Guardrails for AI Agent OperationsP7/10A middleware layer that sits between AI agents and cloud/API services, enforcing hard spending limits, rate controls, and anomaly detection before any resource is consumed.
Prepaid Spending Caps for Cloud and API ServicesC6/10A financial wrapper service that lets developers provision hard-capped, prepaid budgets for cloud and API usage — once the balance hits zero, all calls stop instantly.